The impact of medicines for weight loss on the risk of cancer revealed in a new study

Medications for weight loss and bariatric surgery have been found effective to help people spill excess pounds, and now a new study explores their bond with the risk of cancer (orc) related to obesity.

Obesity is a risk factor known to certain types of cancers and has also been shown to affect cancer survival.

Obesity -related cancers include multiple myeloma, meningioma, esophagus adenocarcinoma; Duct of the stomach, colorectal, liver or biliary, biliary, pancreas, uterus, ovary, kidney kidney, thyroid and breast cancer in postmenopause, according to the disease control and prevention centers (CDC).

Semaglutide had a shocking benefit for patients with liver disease in a new study

Researchers at Clalit Health Services in Tel Aviv, Israel, conducted an observational study of the medical records of 6,356 24 -year -old participants and more who had obesity and diabetes, without a history of cancer related to obesity.

Between 2010 and 2018, half of the participants took agonists from the GLP-1 (GLP-1) receptor-injectable members of obesity and diabetes type 2-With at least six purchases of medicines within 12 months. The other half underwent bariatric metabolic surgery (BMS).

After adjusting to other factors, researchers determined that the OrC occurred in 5.62 cases per 1,000 years of the year in which they had surgery and in 5.89 cases per 1,000 people-years among those who took GPP-1.

In general, the study determined that “the direct GLP1-RAS effect compared to BMS on the risk of orc beyond its effects on weight loss is calculated as 41% of relative risk reduction.”

This is why belly fat is more common as we grow old and three ways to avoid

The findings were published in the journal EclinicalMedicine.

“The results point to the existence of additional avenues beyond the weight loss in which GLP-1 contributes to a decrease in risk of cancer related to obesity,” Fox News Digital, author of the main study, told Fox News.

How do GLP-1 risk of cancer affect?

Niketa Patel, a Molecular Medicine Professor with the USF Health Morsani College of Medicine in Tampa, Florida, said that obesity is associated with chronic inflammation.

“It is shown that GLP1-RAS reduces inflammation and, therefore, decreases the risk of developing orc,” he told Fox News Digital. (Patel did not participate in the study.)

“The anti -inflammatory properties of these medicines address a risk factor known to various cancers.”

“Summary: Obesity can cause certain cancers and the treatment of GLP1-RA obesity reduces the risk of only cancers related to obesity.”

Dr. Britta Remerson, MD, medical director of Knowwell, a healthcare service provider, said that there are several ways in which GLP-1 Ras could have cancer mitigation properties.

“First, the anti -inflammatory properties of these medicines address a risk factor known to various cancers,” said the Minnesota -based doctor, who was also part of the research, told Fox News Digital.

“Secondly, metabolic regulation and the improvement of metabolic health of these medicines, including decreasing blood glucose levels and decreases insulin resistance, can reduce the risk of cancer.”

Emerging evidence also suggests that Ras GLP-1 can have direct antitumor effects, Kitorson said: “Potentially by modulating immune answers and epigenetic changes (changes that occur in gene expression and transmitted to future generations).”

First GLP-1 pill for weight loss, diabetes is successful in a late phase test

Research suggests that GLP-1 medications help reduce inflammation not only through weight loss, but also in other body bodies, such as the heart, according to Dr. Susan Saveery, MD, a medicine certified by the Board and a Primary Care Doctor with Plushcare, a virtual health platform that offers primary care, therapy and weight management services.

“Over time, chronic inflammation can be a risk factor for cancer development, as it can damage cell DNA,” Fox News Digital Savere, who was not involved in the study, told Fox News News.

“Our fat cells (adipose tissue) naturally produce inflammatory cells and GLP-1 medicines, similar to bariatric surgery, help reduce this inflammation by reducing the amount of adipose tissue by weight loss.”

Potential limitations

The study had some limitations, according to researchers.

“First, it is an observational study. It means that our comparison groups (people who had versus surgery received GLP1-RAS) can still have some residual differences, despite our methodological efforts,” Sagy told Fox News Digital.

Click here to get the Fox News app

“However, only this type of real life observational study can provide the long follow -up period needed to evaluate the risk of developing cancer, which often has very long latency periods.”

Another limitation is that the primary drug included in the study was the liraglutide (saxenda, Victoza), with a smaller number of people who took exatida (Byetta) and Dulaglutide (TRULICITY).

“It will be important to evaluate the comparative effectiveness of the new GLP1-RA drugs, which are expected to have a greater effect,” said Sagy.

“Although the direction of the results is promising, we have to wait and see if and how will the clinical guidelines consider it.”

Click here to register -you are in our health newsletter

Readerson agreed that much more research was needed before Ras GLP-1 could be considered as cancer prevention options.

“Larger, random and controlled essays are needed to confirm the observed effects and better understand the underlying mechanisms,” he said.

“It will also be important to investigate the impact of Ras GLP-1 on different types of cancer and to evaluate long-term safety and the potential side effects of the use of Ras GLP-1 as a cancer therapy.”

Saldery agrees that it is likely to be too early to predict FDA approval for cancer therapy, but said that “weight reduction plays a significant role in cancer prevention and that GPP-1 seem to offer additional benefit by reducing inflammation.”

For more health items, visit www.foxnews.com/health

While GLP-1 RAS are “wonderful tools” that can support people in weight loss displacement, Savery said that maintaining a healthy lifestyle through regular nutritional food and regular physical activity is “the basis for cancer prevention and better general health”.